Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.31 |
| ▸ | GLRB | P48167 | 1/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | RHEB | Q15382 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891990 | 0.90 | MAPK10 (0.37) | HDAC8HDAC6HDAC2ALDH1A1MAPK10 | |
| SCHEMBL4903501 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MAPK10MCHR1KDM4ERHEB | |
| SCHEMBL4901549 | 0.73 | ALDH1A1 (0.34) | HDAC8HDAC6ALDH1A1MAPK10HDAC1 | |
| SCHEMBL4891795 | 0.73 | ALDH1A1 (0.34) | HDAC8HDAC6ALDH1A1MAPK10HDAC1 | |
| SCHEMBL4891960 | 0.72 | GCGR (0.34) | HDAC6HDAC2ALDH1A1MAPK10HDAC1 | |
| SCHEMBL4901698 | 0.71 | ALDH1A1 (0.38) | ALDH1A1MAPK10MCHR1KDM4ERHEB | |
| SCHEMBL4901306 | 0.70 | ALDH1A1 (0.39) | ALDH1A1MAPK10MCHR1KDM4ERHEB | |
| SCHEMBL4895489 | 0.70 | ALDH1A1 (0.39) | HDAC8HDAC6ALDH1A1MAPK10HDAC1 | |
| SCHEMBL4898669 | 0.70 | ALDH1A1 (0.39) | HDAC8HDAC6ALDH1A1MAPK10HDAC1 | |
| SCHEMBL4954856 | 0.69 | MCHR1 (0.33) | ALDH1A1MAPK10MCHR1KDM4ERHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | HDAC8 2655/4885HDAC6 2822/4885HDAC2 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.